<DOC>
	<DOC>NCT00422955</DOC>
	<brief_summary>Fluid management study in patients with type 2 diabetes and autonomic neuropathy.</brief_summary>
	<brief_title>Fluid Retention in Rosiglitazone Treated Subjects With Autonomic Neuropathy.</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Inclusion criteria: Subjects with Type 2 Diabetes (T2DM) as defined by the 1999 WHO criteria [World Health Organisation , 1988/NCD/NCS/99.2] with stable FPG of = 7.0 and = 15.0 mmol/l who have been established on insulin therapy for at least 6 months BMI = 40 kg.m2 Subject who is willing and able to provide a signed and dated written informed consent. Subjects with an HbA1c level &gt; 12% Subjects taking oral hypoglycaemic agents other than metformin Subjects on insulin dosage &gt; 200 units/day</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>fluid retention</keyword>
	<keyword>Autonomic Neuropathy</keyword>
</DOC>